Partnerships Develop New Drugs for Third-World Nations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Partnerships Develop New Drugs for Third-World Nations
New collaborative research models plus industry mindset yield treatments for neglected diseases.


Pharmaceutical Technology


Moreover, recent efforts to expand support for third-world health programs by industrialized nations have been disappointing. A special United Nations session on HIV and AIDS in June failed to gain commitments from donor nations to higher treatment goals and funding levels. And, at their July summit, leaders of the Group of Eight industrialized nations sidestepped a proposal for a multibillion-dollar advance market commitment fund to support development of new vaccines.

Fortunately, private donors have remained generous. The Gates Foundation announced in July that it will award $287 million in grants over five years to 16 scientific teams around the world that aim to develop the long-sought AIDS vaccine. The subsequent announcement that Warren Buffett will donate $31 billion to the Gates Foundation is likely to further expand the organization's support for multiple research efforts. Researchers believe that if governmental aid programs matched these levels, many new treatments would emerge fairly quickly.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here